期刊文献+

Advances in management of type 1 diabetes mellitus 被引量:3

Advances in management of type 1 diabetes mellitus
下载PDF
导出
摘要 Treatment of type 1 diabetes mellitus has always posed a challenge to balance hyperglycemia control with hypoglycemia episodes. The quest for newer therapies is continuing and this review attempts to outline the recent developments. The insulin molecule itself has got moulded into different analogues by minor changes in its structure to ensure well controlled delivery, stable half-lives and lesser side effects. Insulin delivery systems have also consistently undergone advances from subcutaneous injections to continuous infusion to trials of inhalational delivery. Continuous glucose monitoring systems are also becoming more accurate and user friendly. Smartphones have also made their entry into therapy of diabetes by integrating blood glucose levels and food intake with calculated adequate insulin required. Artificial pancreas has enabled to a certain extent to close the loop between blood glucose level and insulin delivery with devices armed with meal and exercise announcements, dual hormone delivery and pramlintide infusion. Islet, pancreas-kidney and stem cells transplants are also being attempted though complete success is still a far way off. Incorporating insulin gene and secretary apparatus is another ambitious leap to achieve insulin independence though the search for the ideal vector and target cell is still continuing. Finally to stand up to the statement, prevention is better than cure, immunological methods are being investigated to be used as vaccine to prevent the onset of diabetes mellitus. Treatment of type 1 diabetes mellitus has always posed a challenge to balance hyperglycemia control with hypoglycemia episodes. The quest for newer therapies is continuing and this review attempts to outline the recent developments. The insulin molecule itself has got moulded into different analogues by minor changes in its structure to ensure well controlled delivery, stable half-lives and lesser side effects. Insulin delivery systems have also consistently undergone advances from subcutaneous injections to continuous infusion to trials of inhalational delivery. Continuous glucose monitoring systems are also becoming more accurate and user friendly. Smartphones have also made their entry into therapy of diabetes by integrating blood glucose levels and food intake with calculated adequate insulin required. Artificial pancreas has enabled to a certain extent to close the loop between blood glucose level and insulin delivery with devices armed with meal and exercise announcements, dual hormone delivery and pramlintide infusion. Islet, pancreas-kidney and stem cells transplants are also being attempted though complete success is still a far way off. Incorporating insulin gene and secretary apparatus is another ambitious leap to achieve insulin independence though the search for the ideal vector and target cell is still continuing. Finally to stand up to the statement, prevention is better than cure, immunological methods are being investigated to be used as vaccine to prevent the onset of diabetes mellitus.
出处 《World Journal of Diabetes》 SCIE CAS 2014年第5期689-696,共8页 世界糖尿病杂志(英文版)(电子版)
关键词 Type 1 diabetes ADVANCES INSULIN ANALOGUES CLOSED loop system Continuous GLUCOSE MONITORS INSULIN gene therapy Type 1 diabetes advances Insulin analogues Closed loop system Continuous glucose monitors Insulin gene therapy
  • 相关文献

参考文献11

  • 1Tran, Joseph,Tran, Rosanna,White, John R.Smartphone-Based Glucose Monitors and Applications in the Management of Diabetes: An Overview of 10 Salient "Apps" and a Novel Smartphone-Connected Blood Glucose Monitor[J]. EN . 2012 (4)
  • 2Simon Heller,John Buse,Miles Fisher,Satish Garg,Michel Marre,Ludwig Merker,Eric Renard,David Russell-Jones,Areti Philotheou,Ann Marie Ocampo Francisco,Huiling Pei,Bruce Bode.Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial[J]. The Lancet . 2012 (9825)
  • 3Dimitrios T. Karamitsos.The story of insulin discovery[J]. Diabetes Research and Clinical Practice . 2011
  • 4Christopher C Patterson,Gisela G Dahlquist,Eva Gyürüs,Anders Green,Gyula Soltész.Incidence trends for childhood type 1 diabetes in Europe during 1989–2003 and predicted new cases 2005–20: a multicentre prospective registration study[J]. The Lancet . 2009 (9680)
  • 5M. D.Bellin,R.Kandaswamy,J.Parkey,H.‐J.Zhang,B.Liu,S. H.Ihm,J. D.Ansite,J.Witson,P.Bansal‐Pakala,A. N.Balamurugan,K.Papas,D. E. R.Sutherland,A.Moran,B. J.Hering.Prolonged Insulin Independence After Islet Allotransplants in Recipients with Type 1 Diabetes[J]. American Journal of Transplantation . 2008 (11)
  • 6TARUN K. MANDAL.Inhaled insulin for diabetes mellitus[J]. American Journal of Health-System Pharmacy . 2005 (13)
  • 7Philipp C.Nett,Hans W.Sollinger.Hepatic Insulin Gene Therapy in Insulin‐Dependent Diabetes Mellitus[J]. American Journal of Transplantation . 2003 (10)
  • 8John A Corbett.K cells: a novel target for insulin gene therapy for the prevention of diabetes[J]. Trends in Endocrinology & Metabolism . 2001 (4)
  • 9Katrina A Goodge,John C Hutton.Translational regulation of proinsulin biosynthesis and proinsulin conversion in the pancreatic β -cell[J]. Seminars in Cell and Developmental Biology . 2000 (4)
  • 10James H. Anderson,Rocco L. Brunelle,Veikko A. Koivisto,Michael E. Trautmann,Louis Vignati,Richard DiMarchi.Improved mealtime treatment of diabetes mellitus using an insulin analogue[J]. Clinical Therapeutics . 1997 (1)

共引文献2

同被引文献6

引证文献3

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部